Brokerages expect Urogen Pharma Ltd (NASDAQ:URGN) to post ($1.20) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Urogen Pharma’s earnings, with the lowest EPS estimate coming in at ($1.33) and the highest estimate coming in at ($1.11). Urogen Pharma reported earnings per share of ($1.14) in the same quarter last year, which would suggest a negative year-over-year growth rate of 5.3%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, August 13th.
According to Zacks, analysts expect that Urogen Pharma will report full year earnings of ($5.37) per share for the current year, with EPS estimates ranging from ($5.83) to ($4.82). For the next year, analysts anticipate that the business will post earnings of ($4.23) per share, with EPS estimates ranging from ($6.33) to ($1.66). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Urogen Pharma.
Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.01. Urogen Pharma had a negative return on equity of 61.24% and a negative net margin of 4,296.08%.
Shares of NASDAQ:URGN opened at $35.25 on Monday. The stock has a market cap of $504.63 million, a P/E ratio of -7.34 and a beta of 1.32. Urogen Pharma has a 12-month low of $33.37 and a 12-month high of $56.91.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Private Advisors LLC purchased a new position in shares of Urogen Pharma in the 1st quarter valued at about $329,000. FMR LLC lifted its stake in Urogen Pharma by 5.8% during the first quarter. FMR LLC now owns 588,203 shares of the company’s stock worth $21,728,000 after purchasing an additional 32,200 shares during the last quarter. Wildcat Capital Management LLC lifted its stake in Urogen Pharma by 27.2% during the first quarter. Wildcat Capital Management LLC now owns 779,003 shares of the company’s stock worth $28,776,000 after purchasing an additional 166,509 shares during the last quarter. Morgan Stanley lifted its stake in Urogen Pharma by 65.4% during the first quarter. Morgan Stanley now owns 24,923 shares of the company’s stock worth $920,000 after purchasing an additional 9,856 shares during the last quarter. Finally, Man Group plc lifted its stake in Urogen Pharma by 49.5% during the first quarter. Man Group plc now owns 178,996 shares of the company’s stock worth $6,612,000 after purchasing an additional 59,260 shares during the last quarter. Institutional investors and hedge funds own 97.86% of the company’s stock.
Urogen Pharma Company Profile
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Recommended Story: What does a bar chart mean for investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.